Identification of biomarkers and new therapies for taxane-induced peripheral neuropathy

DOI Web Site Web Site PubMed 8 References
  • Koyanagi Madoka
    Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital
  • Imai Satoshi
    Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital
  • Nakagawa Takayuki
    Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital
  • Matsubara Kazuo
    Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital

Bibliographic Information

Other Title
  • シュワン細胞に着目したタキサン系抗がん薬誘発末梢神経障害のバイオマーカーおよび新規予防／治療薬の探索
  • シュワン サイボウ ニ チャクモク シタ タキサンケイ コウガンクスリ ユウハツ マッショウ シンケイ ショウガイ ノ バイオマーカー オヨビ シンキ ヨボウ/チリョウヤク ノ タンサク

Search this article

Abstract

<p>Chemotherapy-induced peripheral neuropathy (CIPN) is a side effect frequently caused by taxanes. Because the mechanisms underlying CIPN pathogenesis remain to be fully elucidated, there is no indicator for objective diagnosis like a biomarker. In addition, treatment options for CIPN is still unsatisfactory. We have previously demonstrated that paclitaxel preferentially impair myelin-forming Schwann cells, and consequently induce dedifferentiation and demyelination of Schwann cells. Recently, in a paclitaxel CIPN model mouse, we found that an inflammatory factor is released from dedifferentiated Schwann cells in the mouse sciatic nerve into the blood, highly correlated with the on-set of mechanical hypersensitivity. On the other hand, considering our previous findings, it seems that some drugs, which supply newly formed mature Schwann cells at the sites of demyelinated lesions, may be a new beneficial therapy for taxane-induced peripheral neuropathy. In this review, we will introduce our findings about new therapeutic drug candidate for taxane-related CIPN based on this concept, and plasma biomarker to detect CIPN on-set and progression.</p>

Journal

References(8)*help

See more

Related Projects

See more

Keywords

Details 詳細情報について

Report a problem

Back to top